Scholar Rock (NASDAQ:SRRK) now covered by HC Wainwright

HC Wainwright equity research analysts have begun covering the shares of Scholar Rock (NASDAQ:SRRK – Get a Grade) in a research report released Wednesday, reports The Fly. The brokerage has set a “buy” rating on the stock.
SRRK has been the subject of a number of other research reports. Zacks Investment Research upgraded Scholar Rock from a “sell” rating to a “hold” rating in a Friday, March 11 research note. Wedbush reissued an “outperform” rating and published a target price of $50.00 on Scholar Rock shares in a research note on Monday, March 7. Finally, Jefferies Financial Group downgraded Scholar Rock from a “buy” rating to a “hold” rating and reduced its target price for the company from $52.00 to $28.00 in a Wednesday 22 research note. December. Two equity research analysts gave the stock a hold rating and three gave the company a buy rating. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $44.67.
Scholar Rock shares opened at $12.99 on Wednesday. The company has a market capitalization of $458.51 million, a PE ratio of -3.62 and a beta of 0.30. Scholar Rock has a fifty-two week low of $11.35 and a fifty-two week high of $60.08. The stock has a fifty-day moving average price of $16.60. The company has a current ratio of 4.13, a quick ratio of 4.13 and a debt ratio of 0.28.
Lithium is the undisputed fuel of the green energy revolution. A little-known small-cap lithium mining company in a renowned South American location has begun to attract interest from opportunity-minded investors.
Scholar Rock (NASDAQ:SRRK – Get Rating) last released its quarterly results on Monday, March 7. The company reported ($0.97) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.08. The company posted revenue of $4.05 million for the quarter, versus $4.33 million expected by analysts. Scholar Rock had a negative net margin of 700.46% and a negative return on equity of 64.57%. In the same quarter a year earlier, the company posted ($2.81) earnings per share. As a group, equity research analysts expect Scholar Rock to post year-to-date EPS of -4.35.
A number of hedge funds and other institutional investors have recently bought and sold shares of SRRK. Wellington Management Group LLP increased its position in Scholar Rock by 124.9% during the third quarter. Wellington Management Group LLP now owns 1,276,488 shares of the company valued at $42,150,000 after purchasing an additional 708,831 shares during the period. Norges Bank purchased a new stake in Scholar Rock during the fourth quarter worth approximately $14,267,000. Morgan Stanley increased its position in Scholar Rock by 312.4% during the second quarter. Morgan Stanley now owns 352,251 shares of the company valued at $10,180,000 after purchasing an additional 266,841 shares during the period. Victory Capital Management Inc. increased its position in Scholar Rock by 25.9% during the fourth quarter. Victory Capital Management Inc. now owns 1,273,193 shares of the company valued at $31,626,000 after purchasing an additional 262,130 shares during the period. Finally, Millennium Management LLC increased its position in Scholar Rock by 325.2% during the second quarter. Millennium Management LLC now owns 173,839 shares of the company valued at $5,024,000 after purchasing an additional 132,956 shares during the period. Institutional investors and hedge funds hold 82.42% of the company’s shares.
Scholar Rock Company Profile (Get a rating)
Scholar Rock Holding Corp. is a biopharmaceutical company. It engages in the development and discovery of innovative drugs. The Company offers a proprietary platform designed to discover and develop monoclonal antibodies that have a high degree of specificity to achieve selective modulation of growth factor signaling.
Read more
This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]
Should you invest $1,000 in Scholar Rock right now?
Before you consider Scholar Rock, you’ll want to hear this.
MarketBeat tracks Wall Street’s top-rated, top-performing research analysts daily and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and Scholar Rock wasn’t on the list.
Although Scholar Rock currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
See the 5 actions here